摘要】 目的 了解干扰素联合大剂量胸腺肽治疗乙肝病毒前C区变异型慢性乙型肝炎的疗效。方法 60例前C区变异型慢性乙型肝炎患者随机分为A、B两组。A组用干扰素α-2b300MU，皮下注射，每日1次，14天后改隔日1次，共6个月。胸腺肽100mg，静滴，每日1次，1个月后改隔日肌肉注射，共6个月。B组单用干扰素α-2b，剂量方法同A组。比较治疗结束时和随访6个月后各组血清HBV DNA阴转率和ALT复常率。结果 A、B两组治疗结束时HBV DNA阴转率分别为73.33%(22例)、53.33%(16例)(P>0.05)。12个月后分别为70.00%(21例)、40.00%(12例)(P<0.05)。治疗结束时HBV DNA阴转者中5例(22.73%)和7例(43.75%)HBV DNA又复阳(P>0.05)，结束时HBV DNA阳性者中4例(50.00%)和3例(21.42%)HBV DNA转阴(P<0.01)。在治疗结束时和随访6个月后ALT复常率两组差异无显著性。结论 干扰素α-2b联合大剂量胸腺肽治疗乙型肝炎病毒前C区变异型慢性乙型肝炎远期疗效优于单用干扰素组.

    关键词 慢性乙型肝炎(CHB) 干扰素α-2b 胸腺肽 胸腺素α 1 (Tα 1 ) 前C区变异型

    The effect of combination therapy with IFNα-2b plus high dose

    of thymosin on chronic hepatitis B patients with HBV pre-core mutant

    Wu Zongdao，Wang Gongda，Xing Guozhen，et al.

    Baogang Hospital Affiliated to Shanghai Second Medicine University，Shanghai201900.

    【Abstract】 Objective To evaluate the efficacy of combination therapy with IFNα-2b and high dose of thyˉmosin on CHB patients with HBV pre-core mutant.Methods 60CHB patients with pre-core mutant HBV were randomly divided into groupA and B.Patients in both groups received IFNα-2b for six months ......